AZD8848

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Butyrylcholinesterase Deficiency

Conditions

Butyrylcholinesterase Deficiency

Trial Timeline

Sep 1, 2010 → Jan 1, 2012

NCT ID

NCT01205867

About AZD8848

AZD8848 is a phase 1 stage product being developed by AstraZeneca for Butyrylcholinesterase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01205867. Target conditions include Butyrylcholinesterase Deficiency.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01205867	Phase 1	Completed	Sep 1, 2010	Jan 1, 2012	Butyrylcholinesterase Deficiency